Article
The Food and Drug Administration has approved a supplemental new drug application for Pliaglis (lidocaine 7 percent, tetracaine 7 percent), a topical anesthetic cream.
Daily Derm Times: February 13, 2025
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
The Dermatology Industry Landscape: Unpacking Mergers and Acquisitions and Other Economic Movements
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
New Study Examines Connection Between Formulation and Benzene Levels in BPO Products
Balancing Biologics and Corticosteroids: Tailored Approaches for Managing Atopic Dermatitis